sponsored
PatientsVille.com Logo

PatientsVille

Lipiodol Medical Research Studies

Up-to-date List of Lipiodol Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Lipiodol Medical Research Studies

Rank Status Study
1 Recruiting Lipiodol as an Imaging Biomarker in Patients With Primary and Metastatic Liver Cancer
Condition: Liver Cancer
Intervention: Drug: Lipiodol
Outcome Measures: Measuring Lipiodol deposition in tumor;   Determining the time period of survival
2 Unknown  188RE-SSS Lipiodol to Treat HepatoCellular Carcinomas
Condition: Hepatocellular Carcinomas
Intervention: Drug: 188Re-SSS Lipiodol
Outcome Measures: Maximal tolerated dose;   Bio-availability
3 Recruiting Transarterial Chemoembolization With or Without Lipiodol Chemotherapy in Patient With Unresectable Hepatocellular Carcinoma
Condition: Hepatocellular Carcinoma
Interventions: Other: Procedure:Transarterial embolization;   Other: Procedure/Surgery: Transarterial infusion chemotherapy;   Other: Transarterial Lipiodol chemotharepy
Outcome Measures: overall survival;   Time to progression
4 Recruiting Injection of Cyanoacrylate+Lipiodol vs Cyanoacrylate+Lauromacrogol in Gastric Varices
Conditions: Gastric Varices;   Portal Hypertension
Interventions: Drug: Lipiodol;   Drug: Lauromacrogol
Outcome Measures: bleeding rate of the puncture site;   Rebleeding rate after endoscopic treatment
5 Recruiting Comparing Lipiodol/Ethanol With Drug-eluting Beads (DEB) for Hepatocellular Carcinoma
Condition: Hepatocellular Carcinoma
Interventions: Drug: Drug-Eluting Beads (DEB) with Doxorubicin;   Drug: Lipiodol Ethanol Mixture (LEM)
Outcome Measures: Number of Patients with Post-Embolization Syndrome;   Patients with Encephalopathy After Embolization;   Changes in Quality of Life;   Comparison of Liver Function Tests Results;   Imaging Response;   Number of Patients with Successful Liver Transplant;   Overall Survival
6 Unknown  The In Vitro Fertilization - Lipiodol Uterine Bathing Effect Study
Conditions: Endometriosis;   In Vitro Fertilization Implantation Failure
Interventions: Procedure: Lipiodol + IVF;   Procedure: IVF
Outcome Measures: Live birth;   Clinical pregnancy;   Adverse events
7 Recruiting Treatment of Cirrhosis-related Hepatocellular Carcinoma With the Intrahepatic Arterial Injection of an Emulsion of Lipiodol and Idarubicin (Zavedos®): Phase I Study
Conditions: Unresectable Non-metastatic Hepatocellular Carcinoma;   Child A/B7 Cirrhosis
Interventions: Drug: Zavedos®;   Other: Blood samples
Outcome Measures: tolerance: toxicity will be evaluated according to the NCI CTC AE version 4.03 scale to determine the limiting dose;   Study the pharmacokinetics of idarubicin in this delivery method;   Evaluate overall survival;   Evaluate progression-free survival;   Evaluate time to progression;   Evaluate the rate of objective response
8 Recruiting EUS-guided Ethanol-Lipiodol Ablation of Pancreatic Neuroendocrine Tumor: a Prospective Feasibility Study
Conditions: Feasibility;   Safety
Intervention: Procedure: EUS-guided ethanol ablation
Outcome Measures: Number of participants with treatment response;   The number of pariticipants with post-procedure adverse events
9 Recruiting Comparison of Two Solvents Used With Chemotherapy Agent for Transarterial Chemoembolization of Hepatocellular Carcinoma
Condition: Hepatocellular Carcinoma
Interventions: Other: transarterial chemoembolization(TACE);   Other: Transarterial chemoembolization (TACE)
Outcome Measures: overall survival;   Time to progression
10 Recruiting HepaSphere/Quadrasphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Cancer
Condition: Hepatocellular Carcinoma
Interventions: Device: HepaSphere/QuadraSphere Microspheres;   Procedure: PVA, Lipiodol, doxorubicin
Outcome Measures: Median overall survival;   Objective Response Rates (ORR);   ORR in the treated area;   Adverse Events;   Resource utilization
11 Recruiting RCT on Adjuvant TACE After Hepatectomy for HCC
Condition: Hepatocellular Carcinoma
Intervention: Procedure: Transarterial chemoembolisation using cisplatin-Lipiodol mixture
Outcome Measures: 1-year recurrence rate;   Disease-free survival;   Overall Survival;   Complications of transarterial chemoembolisation;   Health-related quality of life assessment
12 Recruiting TACE Plus Recombinant Human Adenovirus for Hepatocellular Carcinoma
Condition: Hepatocellular Carcinoma
Interventions: Drug: Recombinant Human Adenovirus Type 5 Injection;   Procedure: Transartery Chemoembolization
Outcome Measures: Overall survival time;   Number of adverse events;   Tumor response
13 Unknown  Synergistic Treatment for Hepatocellular Carcinoma (HCC) Using TACE With Antiangiogenesis
Condition: Hepatocellular Carcinoma
Intervention: Procedure: Transcatheter Arterial Chemoembolization
Outcome Measures: Safety and tolerability, Mortality;   Tumor volumetry, Changes of Tumor markers such as AFP, Curriculum survival
14 Recruiting Everolimus After (Chemo)Embolization for Liver Metastases From Digestive Endocrine Tumors
Conditions: Neuroendocrine Tumors;   Hepatic Metastases;   Metastases
Interventions: Drug: Everolimus;   Device: embolization;   Drug: Doxorubicin
Outcome Measures: Rate of hepatic progression free survival at 24 months;   Progression free survival rate (hepatic or not) at 24 months;   Overall survival rate;   Toxicities treatment;   Safety;   Tolerability of the treatment
15 Not yet recruiting Adjuvant Radiotherapy Comparing TACE for Curative HCC
Condition: Hepatocellular Carcinoma
Interventions: Other: Transarterial chemoembolization;   Other: Radiotherapy
Outcome Measures: Overall survivals;   Recurrence rates
16 Recruiting Combine TACE and RFA Versus RFA Monotherapy in Unilobar HCC of 3.1 to 7 cm Patient
Condition: Hepatocellular Carcinoma
Interventions: Procedure: Transcatheter Arterial Chemoembolization;   Procedure: Radiofrequency ablation;   Drug: Doxorubicin
Outcome Measures: The rate of complete necrosis (CN);   Primary technique effectiveness;   local tumor progression of HCC;   Survival;   Major complication
17 Recruiting Transcatheter Arterial Chemoembolization Combined With Sorafenib for Unresectable Hepatocellular Carcinoma
Conditions: Hepatocellular Carcinoma;   Face Cancer
Interventions: Procedure: TACE-Sorafenib group;   Procedure: TACE
Outcome Measures: Effectiveness of sorafenib combined with TACE;   Time to progression
18 Recruiting TACE and Adefovir Compared With Transarterial Chemoembolization (TACE) Alone for Hepatitis B Virus (HBV)-Related Unresectable Hepatocellular Carcinoma (HCC)
Conditions: Hepatitis B Virus;   Hepatocellular Carcinoma
Interventions: Drug: adefovir;   Procedure: TACE
Outcome Measures: the progression free survival (PFS);   the rate of overall survival
19 Recruiting Sorafenib Chemoembolization Evaluation Controlled Trial
Condition: Hepatocellular Carcinoma
Interventions: Drug: Sorafenib;   Procedure: TACE
Outcome Measures: Overall survival;   Time to progression;   Tumor response;   Adverse events
20 Unknown  Efficacy of Postoperative Adjuvant Treatments for Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis
Condition: Hepatocellular Carcinoma
Intervention: Other: PVIC, TACE
Outcome Measures: Overall Survival;   Time to Recurrence

These studies may lead to new treatments and are adding insight into Lipiodol etiology and treatment.

A major focus of Lipiodol research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Lipiodol